García-Albéniz Xabier, Gallego Rosa, Hofheinz Ralf Dieter, Fernández-Esparrach Gloria, Ayuso-Colella Juan Ramón, Bombí Josep Antoni, Conill Carles, Cuatrecasas Miriam, Delgado Salvadora, Ginés Angels, Miquel Rosa, Pagés Mario, Pineda Estela, Pereira Verónica, Sosa Aarón, Reig Oscar, Victoria Iván, Feliz Luis, María de Lacy Antonio, Castells Antoni, Burkholder Iris, Hochhaus Andreas, Maurel Joan
Xabier García-Albéniz, Department of Epidemiology, Harvard School of Public Health, Boston, MA 02115, United States.
World J Gastroenterol. 2014 Nov 14;20(42):15820-9. doi: 10.3748/wjg.v20.i42.15820.
AIM: To evaluate the long-term results of conventional chemoradiotherapy and laparoscopic mesorectal excision in rectal adenocarcinoma patients without adjuvant therapy. METHODS: Patients with biopsy-proven adenocarcinoma of the rectum staged cT3-T4 by endoscopic ultrasound or magnetic resonance imaging received neoadjuvant continuous infusion of 5-fluorouracil for five weeks and concomitant radiotherapy. Laparoscopic surgery was planned after 5-8 wk. Patients diagnosed with ypT0N0 stage cancer were not treated with adjuvant therapy according to the protocol. Patients with ypT1-2N0 or ypT3-4 or N+ were offered 5-fluorouracil-based adjuvant treatment on an individual basis. An external cohort was used as a reference for the findings. RESULTS: One hundred and seventy six patients were treated with induction chemoradiotherapy and 170 underwent total mesorectal excision. Cancer staging of ypT0N0 was achieved in 26/170 (15.3%) patients. After a median follow-up of 58.3 mo, patients with ypT0N0 had five-year disease-free and overall survival rates of 96% (95%CI: 77-99) and 100%, respectively. We provide evidence about the natural history of patients with localized rectal cancer achieving a complete response after preoperative chemoradiation. The inherent good prognosis of these patients will have implications for clinical trial design and care of patients. CONCLUSION: Withholding adjuvant chemotherapy after complete response following standard neoadjuvant chemoradiotherapy and laparoscopic mesorectal excision might be safe within an experienced multidisciplinary team.
目的:评估在未接受辅助治疗的直肠腺癌患者中,传统放化疗及腹腔镜直肠系膜切除术的长期疗效。 方法:经内镜超声或磁共振成像分期为cT3 - T4且活检证实为直肠腺癌的患者接受为期五周的新辅助5-氟尿嘧啶持续静脉输注及同步放疗。计划在5 - 8周后行腹腔镜手术。根据方案,诊断为ypT0N0期癌症的患者不接受辅助治疗。ypT1 - 2N0或ypT3 - 4或N +的患者根据个体情况接受以5-氟尿嘧啶为基础的辅助治疗。将一个外部队列作为研究结果的对照。 结果:176例患者接受了诱导放化疗,170例接受了全直肠系膜切除术。170例患者中有26例(15.3%)达到ypT0N0癌症分期。中位随访58.3个月后,ypT0N0患者的五年无病生存率和总生存率分别为96%(95%CI:77 - 99)和100%。我们提供了关于局部直肠癌患者术前放化疗后达到完全缓解的自然病程的证据。这些患者固有的良好预后将对临床试验设计和患者护理产生影响。 结论:在经验丰富的多学科团队中,标准新辅助放化疗及腹腔镜直肠系膜切除术后达到完全缓解后不进行辅助化疗可能是安全的。
World J Gastroenterol. 2014-11-14
Gastroenterol Res Pract. 2025-2-18
J Natl Compr Canc Netw. 2018-7
Gastrointest Endosc. 2011-8